Vertex Is The First To Get NaV1.8 To Proof Of Concept For Pain
Effort Is Built On Decades Of Sodium Channel Research
Executive Summary
Chief scientific officer David Altshuler talked to Scrip about the late-stage development plan for a drug that could represent a blockbuster-sized commercial opportunity, after two Phase II studies testing VX-548 met their primary endpoints.
You may also be interested in...
As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance
Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.
Vertex Diabetes Cell Therapy Trial On Hold – As First Patient Free From Insulin Injections
Vertex expresses surprise at the US FDA’s call for a halt, as it reveals an exciting milestone reached - the first trial participant now producing their own insulin.
Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety
The nerve growth factor inhibitor for osteoarthritis pain is one of the last still in development after safety largely sidetracked the class of drugs.